Vestcor Inc Invests $784,000 in BioNTech SE (NASDAQ:BNTX)

Vestcor Inc purchased a new position in shares of BioNTech SE (NASDAQ:BNTX) during the third quarter, HoldingsChannel reports. The firm purchased 6,600 shares of the company’s stock, valued at approximately $784,000.

Several other large investors have also recently added to or reduced their stakes in the company. Planning Capital Management Corp raised its stake in shares of BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after buying an additional 450 shares in the last quarter. Blue Trust Inc. raised its position in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares in the last quarter. GAMMA Investing LLC lifted its holdings in BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after acquiring an additional 111 shares during the period. Daiwa Securities Group Inc. boosted its position in shares of BioNTech by 430.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after purchasing an additional 1,562 shares in the last quarter. Finally, Caprock Group LLC acquired a new position in shares of BioNTech during the 2nd quarter worth $206,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on BNTX. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 26th. BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. Bank of America boosted their target price on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the company from $90.00 to $137.00 in a research report on Friday, November 8th. Finally, Canaccord Genuity Group lifted their price target on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research note on Wednesday, November 27th. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech has a consensus rating of “Moderate Buy” and a consensus target price of $140.76.

BioNTech Trading Up 1.1 %

NASDAQ BNTX opened at $120.69 on Friday. The firm has a market capitalization of $28.93 billion, a price-to-earnings ratio of -57.47 and a beta of 0.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a one year low of $76.53 and a one year high of $131.49. The company’s 50 day moving average price is $113.91 and its 200 day moving average price is $100.17.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the previous year, the business posted $0.73 EPS. The business’s quarterly revenue was up 38.9% on a year-over-year basis. On average, sell-side analysts predict that BioNTech SE will post -3.72 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.